Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

359

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

BIOLOGICAL: Axicabtagene Ciloleucel
DRUG: Platinum-containing Salvage Chemotherapy
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Kite, A Gilead Company